Company Overview
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
Why Investors Should Care
Generates a return on equity of 18.8%, reflecting efficient use of shareholder capital.
Revenue has grown at a 195.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.16.
Recent Developments
- Dec 2025 Revenue of $74.21M (+195.2% YoY); net profit $-29.82M.
- Trailing 12 Months Year-on-year growth — revenue +82.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 195.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 195.17% |
| 1 Year: | 82.10% |
Stock Price Performance
| 1 Year: | +36.14% |
| 6 Months: | - |
| 3 Months: | +55.91% |
| 1 Month: | +5.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)47.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 195.2% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMR Alamar Biosciences, Inc. PHARMA | 29.95 | -41.60 | $2.08B | 0.00% | -26.95% | 18.76% | 195.17% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 13.09M | 16.16M | 26.04M | 29.43M |
| Cost of Revenue | 6.70M | - | 11.58M | - |
| Gross Profit | 6.39M | 8.58M | 14.46M | 17.72M |
| Operating Expenses | 14.94M | - | 26.80M | - |
| Operating Income | -8.55M | -7.92M | -12.35M | -13.53M |
| EBITDA | -6.72M | - | -19.47M | - |
| Interest Expense | 46.00K | - | 223.00K | - |
| Pretax Income | -7.66M | - | -20.86M | - |
| Tax Provision | 0 | - | 464.00K | - |
| Net Income | -7.66M | -7.02M | -21.32M | -13.20M |
| Diluted EPS | -0.12 | -0.62 | -0.32 | -0.22 |
| R&D Expense | 8.30M | 8.89M | 13.02M | 13.82M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 25.14M | 74.21M |
| Cost of Revenue | 16.54M | 32.51M |
| Gross Profit | 8.61M | 41.70M |
| Operating Expenses | 58.17M | 73.04M |
| Operating Income | -49.57M | -31.33M |
| EBITDA | -41.79M | -24.89M |
| Interest Expense | 2.08M | 401.00K |
| Pretax Income | -47.06M | -29.15M |
| Tax Provision | 13.00K | 665.00K |
| Net Income | -47.07M | -29.82M |
| Diluted EPS | -0.71 | -0.45 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 149.51M | 139.99M |
| Current Assets | 106.70M | 94.70M |
| Cash & Equivalents | 26.77M | 30.00M |
| Inventory | 14.41M | 38.48M |
| Receivables | 6.65M | 12.75M |
| Total Liabilities | 282.92M | 298.95M |
| Current Liabilities | 16.59M | 23.73M |
| Long Term Debt | - | 9.81M |
| Total Debt | 33.10M | 41.47M |
| Total Equity | -133.41M | -158.95M |
| Shares Outstanding | 66.52M | 66.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -55.21M | -53.61M |
| Investing Cash Flow | -53.93M | 46.18M |
| Financing Cash Flow | 113.42M | 10.84M |
| Capital Expenditure | -3.39M | -6.38M |
| Free Cash Flow | -58.60M | -59.99M |
| Net Change in Cash | 4.27M | 3.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 34.2% | 56.2% |
| Operating Margin % | -197.2% | -42.2% |
| Net Margin % | -187.2% | -40.2% |
| ROE % | 35.3% | 18.8% |
| ROCE % | -37.3% | -27.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 6.10% | 4.23M | $147.45M |
| 2 | Samsara BioCapital, LLC | 3.57% | 2.48M | $86.44M |
| 3 | T. Rowe Price Investment Management, Inc. | 3.17% | 2.20M | $76.76M |
| 4 | ARK Investment Management, LLC | 1.98% | 1.37M | $47.88M |
| 5 | Braidwell LP | 1.56% | 1.08M | $37.78M |
| 6 | Alliancebernstein L.P. | 1.45% | 1.00M | $34.96M |
| 7 | HHLR Advisors, LTD | 1.38% | 956.46K | $33.33M |
| 8 | Blackrock Inc. | 1.31% | 911.45K | $31.76M |
| 9 | Millennium Management Llc | 1.25% | 865.76K | $30.17M |
| 10 | FMR, LLC | 1.20% | 829.42K | $28.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALMR
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the …
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript
Revenue surged 82% year-over-year to $29.4 million.
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...
Record 60% gross margin and expanded ADDI partnership position the company for 59% annual growth, despite widening net losses and near-term margin fluctuations.
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales
Alamar Biosciences stock has gained 27.2% year to date, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. That mix of strong recent returns and a low value score raises questions about how much opt…
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings cal…
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, subtypes, and trajectorie…
ALMR — Frequently Asked Questions
What is the current share price of Alamar Biosciences, Inc. (ALMR)?
As of 2026-09-19 21:16 PDT, Alamar Biosciences, Inc. (ALMR) trades at $29.95 on NasdaqGS. Its 52-week range is $19.09 to $36.57.
What is the market capitalisation of ALMR?
Alamar Biosciences, Inc. (ALMR) has a market capitalisation of $2.08B on NasdaqGS.
What is the P/E ratio of ALMR?
ALMR trades at a trailing price-to-earnings (P/E) ratio of -41.60. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.42.
What is the return on equity (ROE) of ALMR?
ALMR has a return on equity (ROE) of 18.76%. Its return on capital employed (ROCE) is -26.95%.
Is ALMR a good stock to buy?
This page provides a data-driven analysis of Alamar Biosciences, Inc. (ALMR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.